4//SEC Filing
Albers Jeffrey W. 4
Accession 0000950170-25-081198
CIK 0001815442other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 6:30 PM ET
Size
8.2 KB
Accession
0000950170-25-081198
Insider Transaction Report
Form 4
Albers Jeffrey W.
Director
Transactions
- Sale
Common Stock
2025-06-03$49.00/sh−6,349$311,101→ 0 total - Exercise/Conversion
Common Stock
2025-06-03$10.34/sh+6,349$65,649→ 6,349 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-03−6,349→ 5,000 totalExercise: $10.34Exp: 2030-09-03→ Common Stock (6,349 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001638474
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 6:30 PM ET
- Size
- 8.2 KB